Drug Profile
Influenza A virus vaccines (pandemic) - Protein Sciences Corporation
Alternative Names: ASP 7373; Avian influenza (bird flu) vaccine - Protein Sciences Corporation/UMN Pharma; H7-rHA; HA vaccine for H5N1 (UMN 0501) - Protein Sciences Corporation; HA vaccine for H9N2 (UMN 0901) - Protein Sciences Corporation; Influenza A (H1N1) vaccine - Protein Sciences Corporation/Vaxine; Influenza A virus H5N1 vaccine - UMN Pharma; Influenza A virus H7N9 vaccine - Protein Sciences Corporation; Panblok; PanBlok; Panblok H1/2009; Panblok-H7; Pandemic H5N1 influenza vaccine - Protein Sciences Corporation/UMN Pharma; Pandemic influenza virus (swine flu) vaccine - Vaxine; Recombinant H5 (rH5) pandemic influenza vaccine (Panblok) - Protein Sciences Corporation; Recombinant haemagglutinin (rHA) influenza vaccine; UMN 0901; UMN-0501Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Protein Sciences Corporation
- Developer Ildong Pharmaceutical; Protein Sciences Corporation; UMN Pharma; Vaxine
- Class Influenza A vaccines; Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza A virus H7N9 vaccines; Influenza A virus H9N2 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype
- No development reported Influenza A virus H1N1 subtype; Influenza A virus H9N2 subtype
Most Recent Events
- 13 Feb 2024 Sanofi completes a phase II trial in Influenza A virus H7N9 subtype (Prevention) in USA (IM) (NCT05608005)
- 03 Nov 2022 Phase-II clinical trials in Influenza A virus H7N9 subtype (Prevention) in USA (IM) (NCT05608005)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Influenza-A virus H9N2 subtype(Prevention) in China (IM, Injection)